Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 studyFranco Locatelli, Cristina Díaz de Heredia, Henrique Bittencourt et al.|Blood|2024Cited by 24
Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 studyFranco Locatelli, Cristina Díaz de Heredia, Bülent Antmen et al.|The Lancet Haematology|2024Cited by 18
Ruxolitinib in Pediatric Patients with Treatment-<i>Naïve</i> or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 StudyFranco Locatelli, Cristina Díaz de Heredia, Hyoung Jin Kang et al.|Blood|2022Cited by 11
S245: RUXOLITINIB IN PEDIATRIC PATIENTS WITH TREATMENT-NAIVE OR STEROID-REFRACTORY CHRONIC GRAFT VERSUS HOST DISEASE: PRIMARY FINDINGS FROM THE PHASE II REACH5 STUDYFranco Locatelli, Cristina Díaz de Heredia, Bülent Antmen et al.|HemaSphere|2023Cited by 3